Combining xCT inhibitors with a CSE inhibitor could potentially provide a rapid and innovative solution to combat obesity and other pathologies associated with high cysteine levels, e.g. cystinuria and tumors that require cysteine for growth and progression. Here, SLC7A11 is linked to cystinuria.